# Oncology Research and Treatment

Offizielles Organ von
DGHO – Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie
OeGHO – Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie
DFaG – Deutsche Fatigue Gesellschaft
AIO – Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft e.V.
Mitglied der Deutschen Krebsgesellschaft e.V.

## Editors

**Editor-in-Chief**

M. Hallek, Köln

**Associate Editors**

- W. Janni, Ulm
- U. R. Kleeberg, Hamburg
- H. Lang, Mainz
- M. Mohler, Mainz
- M. Schuler, Essen
- R. Stupp, Zürich

## Editorial Board

<table>
<thead>
<tr>
<th>P. Albers, Düsseldorf</th>
<th>A. Heidenreich, Aachen</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Bausewein, München</td>
<td>U. Herrlinger, Bonn</td>
</tr>
<tr>
<td>L. Bergmann, Frankfurt/M.</td>
<td>A. Hochhaus, Jena</td>
</tr>
<tr>
<td>J. Boos, Münster</td>
<td>R. D. Hofheinz, Mannheim</td>
</tr>
<tr>
<td>P. Brossart, Bonn</td>
<td>F. Honecker, St. Gallen</td>
</tr>
<tr>
<td>W. Budach, Düsseldorf</td>
<td>V. Jacobs, Salzburg</td>
</tr>
<tr>
<td>R. Büttner, Bonn</td>
<td>K. Jordan, Halle</td>
</tr>
<tr>
<td>J. Debus, Heidelberg</td>
<td>U. Keilholz, Berlin</td>
</tr>
<tr>
<td>E. Dippel, Ludwigshafen</td>
<td>J. P. Klussmann, Gießen</td>
</tr>
<tr>
<td>A. Du Bois, Essen</td>
<td>H. Kölbl, Wien</td>
</tr>
<tr>
<td>T. Fehm, Düsseldorf</td>
<td>W. Kuhn, Bonn</td>
</tr>
<tr>
<td>F. Geiser, Bonn</td>
<td>H.-J. Lenz, Los Angeles</td>
</tr>
<tr>
<td>N. Harbeck, München</td>
<td>P. Mallmann, Köln</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>H. Moch, Zürich</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. Possinger, Berlin</td>
</tr>
<tr>
<td>P. Reichardt, Bad Saarow</td>
</tr>
<tr>
<td>S. Reske, Ulm</td>
</tr>
<tr>
<td>I. Rundebaum, Jena</td>
</tr>
<tr>
<td>P. Schönfiski, Leuven</td>
</tr>
<tr>
<td>C. Spitzweg, München</td>
</tr>
<tr>
<td>I. Strohdle, St. Peter-Ording</td>
</tr>
<tr>
<td>S. Ugurel, Graz</td>
</tr>
<tr>
<td>R. Voltz, Köln</td>
</tr>
<tr>
<td>M. Weller, Zürich</td>
</tr>
</tbody>
</table>

## Editorial Office

S. Karger GmbH
Attn. Dr. Steffi Hentzelt
P.O. Box
D-79095 Freiburg
E-mail s.hentzelt@karger.com
Editorial

7 Patients with Advanced Disease: The Value of Patient Reported Outcomes
Gaertner, J.; Becker, G. (Freiburg i.Br.)

Original Articles

11 Effect of Intensity Modulated Radiotherapy Combined with S-1-Based Chemotherapy in Locally Advanced Gastric Cancer Patients

18 Radiotherapy in Patients with Extramammary Paget's Disease – Our Own Experience and Review of the Literature

24 Docetaxel plus S-1 Versus Oxaliplatin plus S-1 for First-Line Treatment of Patients with Advanced Gastric Cancer: A Retrospective Study
Wang, M.; Wu, M.; Wang, W.; Wang, Q.; Wang, Y. (Shanghai)

30 Correlation between Expression of Biological Markers and [18F]Fluorodeoxyglucose Uptake in Endometrial Cancer
Jo, M.-S. (Yangsan); Choi, O.-H. (Yangsan/Busan); Suh, D.-S.; Yun, M.-S.; Kim, S.-J.; Kim, G.-H. (Busan); Jeon, H.-N. (Yangsan)

36 Physical Performance and Psychosocial Status in Lung Cancer Patients: Results from a Pilot Study
Hummler, S.; Thomas, M.; Hoffmann, B.; Gärtner, P. (Heidelberg); Zoz, M. (Waldshut); Huber, G.; Ulrich, C.; Wiskemann, J. (Heidelberg)

42 Clinical Benefit Response in Pancreatic Cancer Trials Revisited
Bernhard, J.; Dietrich, D. (Berne); Glimelius, B. (Uppsala); Bodoky, G. (Budapest); Scheithauer, W. (Vienna); Herrmann, R. (Basel)

49 Survey of German Non-Medical Practitioners Regarding Complementary and Alternative Medicine in Oncology
Koehl, B. (Frankfurt/M.); Muenstedt, K. (Giessen); Micke, O. (Bielefeld); Muecke, R. (Lemgo/Bochum); Buentzel, J. (Nordhausen); Stoll, C. (Bayreuth); Prott, F. (Wiesbaden); Dennert, G.; Send, B. (Berlin); Huebner, J. (Frankfurt/M.)

Novel Insights from Clinical Practice

55 Basaloid Squamous Cell Carcinoma: A Rare Tumor at the Esophagogastric Junction and an Unexpected Durable Complete Response to FOLFOX-4
Cella, C.A.; Carломagno, C. (Naples); Lordick, F. (Leipzig); Moretto, R.; De Stefano, A.; Raimondo, L.; D’Armiento, M.; Camera, L.; Guadagno, E.; Attademo, L.; Feliciano, S.; Matano, E. (Naples)
Contents

Vol. 37, Issue 1–2, February 2014

Letter to the Editor

60 Advance Care Planning in Oncology – Ethical and Medical Competences Are Needed
Schildmann, J. (Bochum); Winkler, E. (Heidelberg)

61 Society Bulletins
64 PharmaForum
69 PharmaNews / Pharma Ticker
75 Meetings and Conferences
79 Guidelines for Authors
80 Contents of Forthcoming Issues
16 Imprint
Submission

Onkologie Research and Treatment is a peer-reviewed journal intended to provide a forum for presentation of all aspects of oncology, including reviews and original articles from hematology and medical oncology, surgical, gynecological and urological oncology, radiology, as well as clinical-experimental oncology. Contributions to pediatric, ENT and dermatological oncology, pathology, biometry, epidemiology, prevention, early diagnosis and psychological care will also be considered. Manuscripts must be submitted online: www.karger.com/ort.

Should you have any problems with electronic submission please contact the Editorial Office:

S. Karger Verlag für Medizin und Naturwissenschaften GmbH
Attn.: Dr. Steffi Hentzel
P.O. Box 70095 Freiburg (Germany)
Tel. +49 761 45 20 725
Fax +49 761 45 20 714
s.hentzel@karger.com

Language

All contributions must be written in English (American or British spelling and grammar).

Types of Papers and Allotted Number of Pages

Please print the manuscript 1 1/2-spaced with 3-cm margins (left and right). Use only one format (normal) for the document.

The text (including the summary) should be limited to the following number of pages:

<table>
<thead>
<tr>
<th>Printed pages</th>
<th>Equals approx. characters*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review Article, Original Article</td>
<td>5</td>
</tr>
<tr>
<td>Novel Insights from Clinical Practice (formerly Case Report)</td>
<td>3</td>
</tr>
<tr>
<td>Ongoing Clinical Trial, Oncological Education, Clinical Information</td>
<td>4</td>
</tr>
<tr>
<td>Letter to the Editor</td>
<td>1</td>
</tr>
<tr>
<td>Others</td>
<td>2</td>
</tr>
</tbody>
</table>

*including title page, summary, illustrations, tables, and references. Tables and figures count for 1,500 characters each. Each additional complete or partial page to print will be charged to the author.

Novel Insights from Clinical Practice (formerly Case Report): The journal only considers case reports with significant new insights or with an extremely unusual and rare condition. Highlighted boxes containing one or two bullet points on 'Established facts' (what is already known) and 'Novel insights' (what new information has been gained) are required and should be placed on the first page of the report. These should highlight the novelty of the clinical observation. The manuscript should be presented with an abstract (max. 200 words), followed by introduction, case report and discussion.

Conditions

Acceptance of a manuscript is based on the evaluation by several reviewers (peer review). Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Once the manuscript is accepted for publication, all usage rights will be retained by the publisher. The assignment of usage rights applies to all print media as well as electronic offline and online media, including the Internet and data bases/data carriers of any kind. Accepted papers, in whole or in part, may not be translated into other languages, or reproduced by any mechanical or electronic means (including photocopying, recording and microcopying), or stored in a retrieval system without the written consent of the publisher. It is the authors' responsibility to obtain permission to produce illustrations, tables, etc. from other publications. The publisher reserves the right to edit the manuscript and decide on the layout.

Disclosure Statement

Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Disclosure statements will be published at the end of the text of the article.

Printed pages Equals approx. characters*
Review Article, Original Article 5 30,000
Novel Insights from Clinical Practice (formerly Case Report) 3 18,000
Ongoing Clinical Trial, Oncological Education, Clinical Information 4 24,000
Letter to the Editor 1 6,000
Others 2 12,000
*including title page, summary, illustrations, tables, and references. Tables and figures count for 1,500 characters each. Each additional complete or partial page to print will be charged to the author.

Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation.

If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Arrangement

Title page: The first page of each paper should indicate the title and a short title for use as running head.

Authors' affiliations and address of correspondence: Each author's full name, followed by their affiliation (hospital, institute etc. where the work was conducted) and the exact postal address of the corresponding author complete with postal code must be given. Please also supply phone and fax numbers, as well as e-mail address.

Key Words: For indexing purposes, a list of 3-5 key words is essential. Whenever possible, use key words such as found in the Medical Subject Headings List (MeSH) of Index Medicus.

Summary: The summary must not exceed 200 words. Summaries of Original Articles and Case Reports should be structured as follows: Background (or Introduction), Patients and Methods (or Material and Methods), Results, Conclusion.

Footnotes: Footnotes should be used only for tables.

Registered Trade Names: When first mentioned, registered trade names must be marked with the superscript registration symbol ® or ™. It is the sole responsibility of the author to ensure that this rule is followed properly.

Tables and Illustrations: Tables and illustrations should be prepared on separate pages. Tables require a heading and figures a legend. The number of figures and tables should be limited and aim to illustrate the text. Figures are listed in the text as (fig. 1), tables as (table 1). Data already mentioned in the text need not be repeated in a table. Accordingly, numbers used in tables need not be repeated in the text. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 600 dpi. Color illustrations are reproduced at the author's expense. One each is charged to the author at EUR 300. + VAT as contribution to the additional reproduction and color printing costs.

References

The list of references should include only the publications cited in the text. The list should not exceed 60 references for reviews. References must be numbered sequentially in the order cited in the text. In the text identify references by Arabic numerals [in square brackets]. Preferably please cite all authors. It is recommended to quote only articles already published or accepted for publication. Please avoid 'in preparation' or 'personal communication'. Authors are responsible for the accuracy and completeness of their references and for correct citation.

Journal titles should be abbreviated according to the Index Medicus system (www.nlm.nih.gov). If a reference manager is used, the style 'Pharmacology' or 'Nephron' should be chosen.

Examples for references can be found at www.karger.com/ort.pl.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Page Charges

There are no page charges for papers that do not exceed the allotted size (cf. types of papers). Each additional complete or partial page is charged to the author at 400.– EUR + VAT.

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer's errors, are charged to the author. No page proofs are supplied.

Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.